Loading

Joe Paterniti – In Memoriam

Joe Paterniti (1969-2017) was a dedicated father and husband. He always put family first. He was an avid bike rider with his son. Joe and Dylan would ride for 30 miles, easily. If you ask…

Message from Jon

My next treatment starts tomorrow, Monday. Back to the Royal Free in London for round 3 of my battle with kidney cancer. Round 1 was the radical nephrectomy in 2013 in Oxford, and Round 2…

Living in the shadow…

Life is a little better. Jon remains in the constant shadow of the grim reaper and yet we find we’ve adjusted more to living in the moment and are both doing ok. The intense shock,…

The Lily Pad Walk

A cancer diagnosis changes everything, a stage four terminal diagnosis changes everything again. There is no control available, and there are no cures, only vague chances to extend life. For us, just now, it is…

Schrödinger’s Cat

My life on immunotherapy  After 9 months on Nivolumab it’s difficult to imagine a time before our fortnightly trips to London from Hereford, or even a time in the future without them.   In 2013 I…

Loading

Lawing to Present on Rare Kidney Cancer at…

KCCure Director of Outreach, Michael B. Lawing to present on RMC awareness. Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference…

Senate Passes FDA Bill

Shortly before the U.S. Senate left for an undeserved paid vacation, they passed a flurry of minor bills including funding for the Food and Drug Administration, the FDA Reauthorization Act, by a vote of 94-1,…

Remembering Fred Atkin

Remembering Fred Atkin by Jay Bitkower on November 7, 2017 Fred Atkin, a charter member and Vice President of ACKC since 2002, passed away unexpectedly on October 30th. He was 79 years old. He is…

The Landscape of Adjuvant Therapy: A Controversy in…

Michael R. Harrison, MDAssociate Professor of MedicineDivision of Medical OncologyDuke Cancer InstituteDuke University Health SystemDurham, North Carolina   Keywords:adjuvant therapy, locoregional, cytokine therapy, S-TRAC, ARISER, ASSURE, PROTECT, disease-free survival, sunitinib, pazopanib.  Corresponding Author: Michael R.…

Combination Immunotherapy and Targeted Therapy: Will New Combinations…

Xin Gao, MDMedical OncologistClaire and John Bertucci Center    for Genitourinary CancersMassachusetts General Hospital    Cancer CenterBoston, Massachusetts   Keywords: Combination therapy, PD-1/PD-L1, immunotherapy, VEGR/VEGFR, anti-angiogenic therapy Corresponding Author: Xin Gao, MD, Massachusetts General Hospital…

Evolving Role of TKI Monotherapy in Front Line…

Keywords: tyrosine kinase inhibitor, monotherapy, front-line, prognostic classification, IMDC model, sunitinib, cabozantinib.  Corresponding Author: Bradley A. McGregor, MD, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston MA, 02215 Email: Bradley_McGregor@DFCI.HARVARD.EDU   Tyrosine kinase inhibitors (TKI) directed…

Loading

ACKC Awards $30,000 Grant to UTSW Researcher

ACKC Awards $30,000 Grant to UTSW Researcher by Jay Bitkower on September 18, 2018 Action to Cure Kidney Cancer recently awarded a $30,000 grant to the University of Texas Southwestern (UTSW) to support the work…

Holiday time, make sure you are prepared.

Holidays; I don’t know about you, but I love planning them especially when the weather is so dismal! Dreaming of an escape from the norm and daily routine. By Susanna Smith, Kidney Cancer Specialist Nurse When you…